Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Westerink

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Cardiovascular Diabetology|September 9, 2021
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular diseaseLisanne C A Smidt, Frank L J Visseren, Wendela L de Ranitz-Greven, et al.
International Journal of Cardiology|August 14, 2017
Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetesSuzanne E Engelen, Yolanda van der Graaf, Manon C Stam-Slob, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 4, 2022
Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes: 10-Year and Lifetime Risk Prediction ModelsHelena Bleken Østergaard, Stephanie H Read, Naveed Sattar, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Diagnosis (Berlin, Germany)|February 28, 2024
HbA<sub>1c</sub> and fasting plasma glucose levels are equally related to incident cardiovascular risk in a high CVD risk population without known diabetesRiemer A Been, Ellen Noordstar, Marga A G Helmink, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|July 28, 2019
Transcranial Doppler 24 Hours after Carotid Endarterectomy Accurately Identifies Patients Not at Risk of Cerebral Hyperperfusion SyndromeLeonie M M Fassaert, Rogier V Immink, Daniël J van Vriesland, et al.
Rheumatology Advances in Practice|August 22, 2022
Patients with diffuse idiopathic skeletal hyperostosis have an increased burden of thoracic aortic calcificationsNetanja I Harlianto, Jan Westerink, Marjolein E Hol, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 2015
Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk PopulationEva J E Hendriks, Jan Westerink, Pim A de Jong, et al.
Rheumatology (Oxford, England)|November 18, 2021
Diffuse idiopathic skeletal hyperostosis is associated with incident stroke in patients with increased cardiovascular riskNetanja I Harlianto, Nadine Oosterhof, Wouter Foppen, et al.
European Heart Journal|September 11, 2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trialTamar I de Vries, John W Eikelboom, Jackie Bosch, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Cardiovascular Diabetology|September 9, 2021
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular diseaseLisanne C A Smidt, Frank L J Visseren, Wendela L de Ranitz-Greven, et al.
International Journal of Cardiology|August 14, 2017
Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetesSuzanne E Engelen, Yolanda van der Graaf, Manon C Stam-Slob, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 4, 2022
Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes: 10-Year and Lifetime Risk Prediction ModelsHelena Bleken Østergaard, Stephanie H Read, Naveed Sattar, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Diagnosis (Berlin, Germany)|February 28, 2024
HbA<sub>1c</sub> and fasting plasma glucose levels are equally related to incident cardiovascular risk in a high CVD risk population without known diabetesRiemer A Been, Ellen Noordstar, Marga A G Helmink, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|July 28, 2019
Transcranial Doppler 24 Hours after Carotid Endarterectomy Accurately Identifies Patients Not at Risk of Cerebral Hyperperfusion SyndromeLeonie M M Fassaert, Rogier V Immink, Daniël J van Vriesland, et al.
Rheumatology Advances in Practice|August 22, 2022
Patients with diffuse idiopathic skeletal hyperostosis have an increased burden of thoracic aortic calcificationsNetanja I Harlianto, Jan Westerink, Marjolein E Hol, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 2015
Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk PopulationEva J E Hendriks, Jan Westerink, Pim A de Jong, et al.
Rheumatology (Oxford, England)|November 18, 2021
Diffuse idiopathic skeletal hyperostosis is associated with incident stroke in patients with increased cardiovascular riskNetanja I Harlianto, Nadine Oosterhof, Wouter Foppen, et al.
European Heart Journal|September 11, 2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trialTamar I de Vries, John W Eikelboom, Jackie Bosch, et al.
Pageof 12